Edesa Biotech

About:

Edesa develops treatments for dermatological and anorectal diseases. Edesa merged with Stellar Biotechnologies in 2019.

Website: http://edesabiotech.com/

Twitter/X: edesabiotech

Top Investors: Government of Canada, Pharmascience, Lumira Ventures, Inveready, Strategic Innovation Fund

Description:

Edesa Biotech is a clinical-stage private company focused on developing treatments for dermatological and anorectal diseases. The initial focus is on developing novel, safe and potent alternatives to steroids for Allergic Contact Dermatitis, Hemorrhoids, and Anal Fissures. Edesa Biotech’s lead asset, EB01 is a novel non-steroidal anti-inflammatory molecule for the treatment of allergic contact dermatitis which has already demonstrated statistically significant improvements in multiple clinical studies.